Prostate-specific antigen-based prostate cancer screening: Reduction of prostate cancer mortality after correction for nonattendance and contamination in the rotterdam section of the european randomized study of screening for prostate cancer

European Urology

Volumn 65, Issue 2, 2014, Pages 329-336

  Bokhorst, Leonard P ^a   Bangma, Chris H ^a   Van Leenders, Geert J L H ^a   Lous, Jan J ^b   Moss, Sue M ^c   Schröder, Fritz H ^a   Roobol, Monique J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b STAR Medical Diagnostic Center   (Netherlands)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Biopsy; Contamination; Nonattendance; PALGA; Prostate specific antigen; Prostatic neoplasms; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SCREENING; CONTROLLED STUDY; DECISION MAKING; GLEASON SCORE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PATIENT PARTICIPATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR;

BIOPSY; CONTAMINATION; NONATTENDANCE; PALGA; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SCREENING;

AGED; BIOPSY; HUMANS; KALLIKREINS; MALE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; ODDS RATIO; PATIENT COMPLIANCE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UP-REGULATION;

EID: 84891825141     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.08.005     Document Type: Article

References (26)

1. M.J. Roobol, R. Kranse, and C.H. Bangma et al. Screening for prostate cancer: results of the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer Eur Urol 64 2013 530 539
2. J. Cuzick, R. Edwards, and N. Segnan Adjusting for non-compliance and contamination in randomized clinical trials Stat Med 16 1997 1017 1029
3. M.J. Roobol, M. Kerkhof, and F.H. Schröder et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC) Eur Urol 56 2009 584 591
4. M.J. Roobol, and F.H. Schröder European Randomized Study of Screening for Prostate Cancer (ERSPC): rationale, structure and preliminary results BJU Int 92 Suppl 2 2003 1 122
5. M.J. Roobol, W.J. Kirkels, and F.H. Schroder Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, The Netherlands) BJU Int 92 Suppl 2 2003 48 54
6. H.J. De Koning, J. Blom, and J.W. Merkelbach et al. Determining the cause of death in randomized screening trial(s) for prostate cancer BJU Int 92 Suppl 2 2003 71 78
7. S. Roemeling, M.J. Roobol, and S.J. Otto et al. Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trial Prostate 67 2007 1053 1060
8. S.J. Otto, I.W. van der Cruijsen, and M.K. Liem et al. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer Int J Cancer 105 2003 394 399
9. M. Casparie, A.T. Tiebosch, and G. Burger et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive Cell Oncol 29 2007 19 24
10. P.A. Van den Brandt, L.J. Schouten, R.A. Goldbohm, E. Dorant, and P.M. Hunen Development of a record linkage protocol for use in the Dutch Cancer Registry for Epidemiological Research Int J Epidemiol 19 1990 553 558
11. M. Kerkhof, M.J. Roobol, and J. Cuzick et al. Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC Section Rotterdam) Int J Cancer 127 2010 2639 2644
12. A.G. Bergdahl, G. Aus, H. Lilja, and J. Hugosson Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees Cancer 115 2009 5672 5679
13. R. Kranse, P.J. van Leeuwen, and T. Hakulinen et al. Excess all-cause mortality in the evaluation of a screening trial to account for selective participation J Med Screen 20 2013 39 45
14. G.L. Andriole, E.D. Crawford, and R.L. Grubb III et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up J Natl Cancer Inst 104 2012 125 132
15. L.P. Bokhorst, X. Zhu, M. Bul, C.H. Bangma, F.H. Schroder, and M.J. Roobol Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial BJU Int 110 2012 1654 1660
16. M.J. Roobol, R. Kranse, and C.H. Bangma et al. Reply from authors re: Michael Baum. Screening for prostate cancer: can we learn from the mistakes of the breast screening experience? Eur Urol 2013;64:540-1: Screening for prostate cancer: we have learned and are still learning Eur Urol 64 2013 541 543
17. M. Popiolek, J.R. Rider, and O. Andrén et al. Natural history of early, localized prostate cancer: a final report from three decades of follow-up Eur Urol 63 2013 428 435
18. M.J. Roobol, and S.V. Carlsson Risk stratification in prostate cancer screening Nat Rev Urol 10 2013 38 48
19. M.J. Roobol, X. Zhu, and F.H. Schröder et al. A calculator for prostate cancer risk 4 years after an initially negative screen: findings from ERSPC Rotterdam Eur Urol 63 2013 627 633
20. M.J. Roobol, H.A. van Vugt, and S. Loeb et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators Eur Urol 61 2012 577 583
21. M.J. Roobol, F.H. Schröder, and E.D. Crawford et al. A framework for the identification of men at increased risk for prostate cancer J Urol 182 2009 2112 2120
22. X. Zhu, P.C. Albertsen, G.L. Andriole, M.J. Roobol, F.H. Schröder, and A.J. Vickers Risk-based prostate cancer screening Eur Urol 61 2012 652 661
23. L.D. Venderbos, L.P. Bokhorst, C.H. Bangma, and M.J. Roobol Active surveillance: oncologic outcome Curr Opin Urol 23 2013 268 272
24. M. Bul, X. Zhu, and R. Valdagni et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study Eur Urol 63 2013 597 603
25. M.A. Dall'Era, P.C. Albertsen, and C. Bangma et al. Active surveillance for prostate cancer: a systematic review of the literature Eur Urol 62 2012 976 983
26. F.H. Schroder, J. Hugosson, and M.J. Roobol et al. Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981 990